How to buy Adaptimmune Therapeutics stock | $5.21

Adaptimmune Therapeutics plc is a biotechnology business based in the US. Adaptimmune Therapeutics shares (ADAP) are listed on the NASDAQ and all prices are listed in US Dollars. Adaptimmune Therapeutics employs 462 staff and has a trailing 12-month revenue of around 0.00.

Adaptimmune Therapeutics stock price (NASDAQ: ADAP)

Use our graph to track the performance of ADAP stocks over time.

Adaptimmune Therapeutics shares at a glance

• Key figures

Information last updated 2021-10-23.

Latest market close	$5.21
52-week range	$3.37 - $7.34
50-day moving average	$5.45
200-day moving average	$4.72
Wall St. target price	$9.83
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.96

Buy Adaptimmune Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Adaptimmune Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Adaptimmune Therapeutics price performance over time

Historical closes compared with the close of $5.21 from 2021-10-22

1 week (2021-10-14)	-4.40%
1 month (2021-09-21)	-5.27%
3 months (2021-07-23)	43.92%
6 months (2021-04-23)	-4.05%

1 year (2020-10-23)	8.54%
2 years (2019-10-24)	482.77%
3 years (2018-10-24)	6.485
5 years (2016-10-24)	6.11%

Is Adaptimmune Therapeutics under- or over-valued?

Valuing Adaptimmune Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Adaptimmune Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Adaptimmune Therapeutics's PEG ratio

Adaptimmune Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.11. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Adaptimmune Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Adaptimmune Therapeutics financials

Revenue TTM	$6.2 million
Gross profit TTM	$-87,610,000
Return on assets TTM	-20.87%
Return on equity TTM	-43.43%
Profit margin	0%
Book value	$1.78
Market capitalisation	$813.2 million

TTM: trailing 12 months

Shorting Adaptimmune Therapeutics shares

There are currently 3.4 million Adaptimmune Therapeutics shares held short by investors – that's known as Adaptimmune Therapeutics's "short interest". This figure is 44.9% down from 6.1 million last month.

There are a few different ways that this level of interest in shorting Adaptimmune Therapeutics shares can be evaluated.

Adaptimmune Therapeutics's "short interest ratio" (SIR)

Adaptimmune Therapeutics's "short interest ratio" (SIR) is the quantity of Adaptimmune Therapeutics shares currently shorted divided by the average quantity of Adaptimmune Therapeutics shares traded daily (recently around 4.0 million). Adaptimmune Therapeutics's SIR currently stands at 0.83. In other words for every 100,000 Adaptimmune Therapeutics shares traded daily on the market, roughly 830 shares are currently held short.

However Adaptimmune Therapeutics's short interest can also be evaluated against the total number of Adaptimmune Therapeutics shares, or, against the total number of tradable Adaptimmune Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Adaptimmune Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Adaptimmune Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0263% of the tradable shares (for every 100,000 tradable Adaptimmune Therapeutics shares, roughly 26 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Adaptimmune Therapeutics.

Find out more about how you can short Adaptimmune Therapeutics stock.

Adaptimmune Therapeutics share dividends

We're not expecting Adaptimmune Therapeutics to pay a dividend over the next 12 months.

Adaptimmune Therapeutics share price volatility

Over the last 12 months, Adaptimmune Therapeutics's shares have ranged in value from as little as $3.37 up to $7.34. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adaptimmune Therapeutics's is 2.1243. This would suggest that Adaptimmune Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Adaptimmune Therapeutics overview

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc. , Alpine Immune Sciences, Inc. , and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc.

Frequently asked questions

What percentage of Adaptimmune Therapeutics is owned by insiders or institutions?
Currently 0.111% of Adaptimmune Therapeutics shares are held by insiders and 80.184% by institutions. How many people work for Adaptimmune Therapeutics?
Latest data suggests 462 work at Adaptimmune Therapeutics. When does the fiscal year end for Adaptimmune Therapeutics?
Adaptimmune Therapeutics's fiscal year ends in December. Where is Adaptimmune Therapeutics based?
Adaptimmune Therapeutics's address is: 60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX What is Adaptimmune Therapeutics's ISIN number?
Adaptimmune Therapeutics's international securities identification number is: US00653A1079 What is Adaptimmune Therapeutics's CUSIP number?
Adaptimmune Therapeutics's Committee on Uniform Securities Identification Procedures number is: 00653A107